Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2006
NCT00419081
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Instituto Estadual de Hematologia Artur de Siqueira Cavalcanti - HEMORIO

Active Ingredients

Drugs in Phase 3 Trials (1)

hydroxyurea (hydrea) (2 trials)

Drugs in Phase 2 Trials (1)

forodesine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Sickle Cell (Phase 3)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2